Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Halozyme Therapeutics insider Helen Torley filed a Form 144 indicating a proposed sale of 240,000 shares of common stock through J.P. Morgan Securities LLC, with an aggregate market value of $23,678,400 as of 08/17/2026. The filing lists 113,498,000 shares of Halozyme common stock outstanding. It also reports prior sales during the past three months totaling 51,923 shares of common stock for aggregate proceeds of $3,523,398 across four transactions.
Halozyme Therapeutics filed a Form 144 indicating an affiliate’s intent to sell common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services group at 1 New York Plaza, New York. The notice reflects planned cash sales tied to stock option exercises on August 11, 2026, including transactions for 32,659, 5,277, and 3,766 shares of common stock.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported a sale of 1,626 shares of common stock on 2026-08-10 at $102.80 per share. After this transaction, she directly holds 40,418 shares. The sale was made under a Rule 10b5-1 written trading plan adopted on May 29, 2025.
Halozyme Therapeutics insider Bernadette Connaughton has filed to potentially sell 1,626 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $167,673.12 on NASDAQ as of a planned sale date of August 10, 2026. These shares relate to Restricted Stock Units granted on April 25, 2025. The filing also lists prior sales under a Rule 10b5-1 trading plan, including 1,625 shares sold on July 1, 2026 for $124,650.66 and 1,625 shares sold on June 1, 2026 for $107,591.25.
Halozyme Therapeutics, Inc., a biopharmaceutical company focused on ENHANZE and auto‑injector drug‑delivery technologies, reported the following results for the three and six months ended June 30, 2026. Total revenues were $480,999 thousand for the quarter and $857,707 thousand for the first half. Quarterly net income was $229,913 thousand, with diluted EPS of $1.90; six‑month net income was $379,962 thousand and diluted EPS $3.11.
Net cash provided by operating activities reached $420,969 thousand in the first half of 2026, while the company repurchased $332,729 thousand of common stock. At June 30, 2026, cash and cash equivalents were $163,138 thousand, available‑for‑sale marketable securities $67,865 thousand and restricted cash $848 thousand. Total assets were $2,577,408 thousand and total liabilities $2,433,865 thousand, including a current portion of long‑term debt of $208,970 thousand and long‑term debt, net, of $1,937,684 thousand.
Stockholders’ equity was $143,543 thousand, supported by retained earnings of $151,259 thousand. Halozyme continues to grow a royalty‑ and product‑driven model through ENHANZE collaborations, Hypercon and Surf Bio hyperconcentration technologies, and device partnerships, while integrating the 2025 Elektrofi acquisition to broaden its portfolio of drug‑delivery platforms.
Halozyme Therapeutics reported record second quarter 2026 results, with total revenue up 48% year-over-year to $481.0 million and royalty revenue up 50% to $307.7 million, driven mainly by ENHANZE partner products such as VYVGART Hytrulo and DARZALEX SC. Operating income reached $287.7 million and net income was $229.9 million. GAAP diluted EPS was $1.90 and Non-GAAP diluted EPS was $2.28. Adjusted EBITDA increased to $328.8 million.
The company raised its 2026 outlook, guiding to total revenue of $1.835–$1.910 billion (31%–37% growth), royalty revenue of $1.220–$1.245 billion (41%–43% growth), adjusted EBITDA of $1.225–$1.280 billion (86%–95% growth) and Non-GAAP diluted EPS of $8.65–$9.00 (108%–117% growth). Halozyme returned capital by repurchasing 4.8 million shares for $332.8 million in the quarter under its buyback programs and expanded its ENHANZE and Hypercon collaboration portfolio through new agreements with partners including GSK, Incyte, Vertex and Oruka.
Halozyme Therapeutics President and CEO Helen Torley exercised stock options for 1,923 shares of common stock at $12.07 per share and immediately sold the same 1,923 shares in open‑market transactions at prices around $79–$80 per share. These trades were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on March 21, 2025, and involved options that were due to expire in February 2027. After these transactions, Torley directly holds 767,780 shares of Halozyme common stock.
HALOZYME THERAPEUTICS EVP David A. Ramsay reported a series of equity compensation transactions. On July 1, 2026 he received an option to buy 39,823 shares of common stock at $77.01 per share and a grant of 16,232 restricted stock units.
On June 30, 2026 10,000 restricted stock units vested and were settled in common shares, with 5,408 shares withheld by the company to cover tax obligations and 4,592 shares remaining directly owned. The filing shows routine grants, vesting, and tax withholding rather than open-market trading.
HALOZYME THERAPEUTICS, INC. reported that SVP and Chief Financial Officer Darren Snellgrove received new equity awards on July 1, 2026. He was granted options to purchase 127,432 shares of common stock at an exercise price of $77.01 per share, along with 41,554 restricted stock units (RSUs).
The options begin vesting one-fourth on the first vesting date and then in equal monthly installments over 48 months, while the RSUs vest in three equal annual installments starting on the first anniversary of the grant date. These are compensation-related grants, not open‑market purchases or sales, and increase the CFO’s potential future ownership if vesting and exercise conditions are met.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported open-market sales of a total of 1,625 shares of common stock. The trades were executed at weighted average prices of about $76 to $77 per share across two price ranges.
The sales were made under a pre-arranged written trading plan adopted on May 29, 2025 in accordance with Rule 10b5-1, indicating these transactions were scheduled in advance as part of ongoing portfolio management rather than discretionary timing decisions.